Financial Performance - The total revenue for 2022 was CNY 3,240,160,465.12, representing a 14.18% increase compared to CNY 2,837,716,899.79 in 2021[25]. - The net profit attributable to shareholders for 2022 was CNY 438,463,234.35, which is a 39.43% increase from CNY 314,473,914.94 in 2021[25]. - The proposed cash dividend for 2022 is CNY 4 per 10 shares, totaling CNY 192,000,000, resulting in a cash dividend payout ratio of 43.79%[5]. - The net profit attributable to shareholders for the year 2022 was CNY 413,494,591.21, representing a 37.07% increase compared to the previous year[26]. - The total assets at the end of 2022 reached CNY 4,321,559,033.18, an increase of 100.71% from the previous year[29]. - Basic earnings per share for 2022 were CNY 1.04, up 19.54% from CNY 0.87 in 2021[30]. - The weighted average return on equity decreased to 20.25% in 2022, down 8.59 percentage points from 28.84% in 2021[30]. - The operating cash flow for the fourth quarter of 2022 was CNY 246,166,080.69, showing a significant increase compared to previous quarters[32]. - The company reported a net cash flow from operating activities of CNY 659,764,826.04 for the year 2022, reflecting a strong operational performance[26]. - The total equity attributable to shareholders increased significantly due to public stock issuance, contributing to the overall growth in net assets[30]. Research and Development - The company invested 23,974.07 million yuan in R&D, representing a year-on-year increase of 33.44%[40]. - The company has established four major technology platforms to support its R&D efforts[49]. - The company has 51 projects in generic drug development and 5 in innovative drug development[50]. - The company is focusing on R&D in major diseases and chronic conditions, employing a dual strategy of high-end generics and innovative drugs[90]. - The company has multiple ongoing R&D projects, including a GLP-1 drug for diabetes and obesity, currently in the drug discovery phase[91]. - The company's R&D investment accounted for 7.40% of its operating revenue, with a total R&D expenditure of 63,425.95 million RMB, which is higher than the industry average of 53,918.03 million RMB[95]. - The company has a capitalized R&D expenditure ratio of 0%, indicating that all R&D expenses were expensed in the current period[95]. Market Strategy and Expansion - The company plans to continue expanding its market presence and investing in new product development to sustain growth in the coming years[30]. - The company plans to expand its market presence through new product launches and strategic partnerships[90]. - The company is actively pursuing mergers and acquisitions to bolster its market position and diversify its product offerings[126]. - The company is expanding its market presence in Southeast Asia, targeting a 20% market share by 2025[121]. - The company is adapting to the dynamic adjustment mechanisms of medical insurance payments, which are becoming more standardized and refined[80]. Environmental Responsibility - The company is committed to safety and environmental protection in production, implementing an information platform for safety production[40]. - The company has established a comprehensive environmental management system to ensure compliance with pollution discharge standards, with all pollutants below regulatory limits[196]. - The company has implemented strategies to manage hazardous waste effectively, with all hazardous waste disposed of by qualified units[173]. - The company has a continuous monitoring system for wastewater and waste gas emissions, ensuring real-time compliance with environmental standards[195]. - The company has actively engaged in ecological protection and green development initiatives, reinforcing its commitment to environmental responsibility[197]. Governance and Compliance - The company is committed to ensuring the authenticity, accuracy, and completeness of the financial report[4]. - The audit report issued by Tianjian Accounting Firm is a standard unqualified opinion[5]. - The governance structure has been enhanced to ensure compliance with laws and regulations, safeguarding the rights of shareholders and creditors[117]. - The company has established a comprehensive internal control system to ensure compliance with legal regulations and protect shareholder rights[163]. - The company has maintained its commitment to transparency in executive compensation, adhering to its internal regulations[134]. Employee Management - The total number of employees in the parent company is 1,680, while the main subsidiaries have 1,576 employees, totaling 3,256 employees[150]. - The company has established a standardized salary management system to enhance the rationality, fairness, and incentive of employee compensation[153]. - The company’s employee compensation includes fixed salary, variable salary, and welfare allowances[153]. - The management team includes experienced professionals with backgrounds in various sectors, ensuring strategic oversight and operational efficiency[127]. Risks and Challenges - The company faces risks related to drug and medical device R&D, including high capital investment, technical challenges, and regulatory changes that could delay product launches[112]. - The ongoing national drug procurement policy may lead to risks of not winning bids or further price reductions, potentially slowing down business performance[112]. - The pharmaceutical industry is experiencing intensified competition in the generic drug sector, with a focus on original drug replacements and increased market concentration[80].

证券代码：601089 证券简称：福元医药 公告编号：临 2023-017 北京福元医药股份有限公司 关于召开 2022 年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 董事长及总经理：黄河先生 http://roadshow.sseinfo.com/） 北京福元医药股份有限公司（以下简称"公司"）已于 2023 年 4 月 18 日发布公司 2022 年度报告，为便于广大投资者更全面深入地了 解公司 2022 年度经营成果、财务状况，公司计划于 2023 年 04 月 25 日 上午 10:00-11:00 举行 2022 年度业绩说明会，就投资者关心的 问题进行交流。 一、 说明会类型 会议召开时间：2023 年 04 月 25 日(星期二) 上午 10:00-11:00 会议召开地点：上海证券交易所上证路演中心（网址： 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 04 月 18 日(星期二) 至 04 月 24 日(星期 一)16:00 前登录上证路演中心网站首页点 ...

Financial Performance - The company's operating revenue for Q3 2022 was approximately ¥822.43 million, representing a 14.06% increase compared to ¥721.06 million in the same period last year[10]. - Net profit attributable to shareholders was approximately ¥125.02 million, a 28.02% increase from ¥97.62 million in the previous year[10]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was approximately ¥113.01 million, reflecting a 19.15% increase from ¥94.80 million year-on-year[10]. - Total operating revenue for the first three quarters of 2022 reached ¥2,365,674,217.96, an increase of 15.7% compared to ¥2,043,484,650.29 in the same period of 2021[34]. - Net profit for Q3 2022 was ¥333,009,164.40, representing a 27% increase from ¥262,492,112.90 in Q3 2021[37]. - Earnings per share for Q3 2022 was ¥0.83, compared to ¥0.72 in Q3 2021, reflecting a 15.3% increase[37]. Assets and Liabilities - Total assets at the end of the reporting period were approximately ¥4.09 billion, an increase of 90.04% compared to the previous year's end[10]. - Shareholders' equity attributable to the parent company was approximately ¥3.07 billion, a significant increase of 153.33% from ¥1.21 billion year-on-year[10]. - Total current assets as of September 30, 2022, reached RMB 3,159,617,178.11, a significant increase from RMB 1,279,419,125.39 in the previous year[24]. - Total liabilities included accounts payable of RMB 114,057,259.70, down from RMB 129,768,747.00, indicating a decrease of about 12%[27]. - The total liabilities increased to ¥1,017,228,732.47, compared to ¥937,856,701.97 in the previous year, marking an 8.5% rise[34]. Cash Flow - The company reported a net cash flow from operating activities of approximately ¥413.60 million for the year-to-date period, up 5.04% from ¥393.76 million in the previous year[10]. - The net cash flow from operating activities for the first three quarters of 2022 was CNY 413,598,745.35, an increase from CNY 393,758,907.86 in the same period of 2021, representing a growth of approximately 3.4%[39]. - Total cash inflow from operating activities amounted to CNY 2,363,991,325.60, compared to CNY 2,078,714,633.90 in the previous year, indicating an increase of about 13.7%[39]. - Cash outflow from operating activities was CNY 1,950,392,580.25, up from CNY 1,684,955,726.04 in 2021, reflecting a rise of approximately 15.7%[39]. - The net cash flow from financing activities was CNY 1,510,419,345.07, contrasting with a negative flow of CNY -28,594,405.95 in the same period of 2021[40]. Shareholder Information - The company reported a total of 53,852 common shareholders at the end of the reporting period[20]. - The top ten shareholders collectively hold 99.99% of the company's shares, with the largest shareholder owning 36.73%[20]. Expenses and Investments - Research and development expenses rose to ¥171,277,340.73, up 42.3% from ¥120,389,823.11 in the previous year[34]. - The company received CNY 100,000,000.00 from other investment-related cash activities, down from CNY 415,000,000.00 in the previous year[39]. - The company paid CNY 407,896,428.45 to employees, which is an increase from CNY 353,444,711.06 in the previous year, reflecting a rise of about 15.4%[39].

Financial Performance - The company's operating revenue for the first half of 2022 was ¥1,543,244,384.17, representing a 16.70% increase compared to ¥1,322,421,434.08 in the same period last year[20]. - The net profit attributable to shareholders of the listed company was ¥206,362,056.15, a 26.57% increase from ¥163,039,091.76 in the previous year[20]. - The net cash flow from operating activities was ¥198,421,969.59, showing a decrease of 12.22% compared to ¥226,044,982.98 in the same period last year[20]. - The net profit after deducting non-recurring gains and losses was ¥193,524,724.80, which is a 22.58% increase from ¥157,877,186.61 in the same period last year[20]. - Basic earnings per share (EPS) for the first half of 2022 was CNY 0.57, an increase of 26.67% compared to the previous period[22]. - Diluted EPS also stood at CNY 0.57, reflecting the same growth rate of 26.67%[22]. - The weighted average return on equity (ROE) increased to 16.37%, up by 0.85 percentage points from the previous period[22]. - The adjusted basic EPS, excluding non-recurring gains and losses, was CNY 0.54, representing a 22.73% increase[22]. Assets and Liabilities - Total assets reached ¥3,957,989,874.18, marking an 83.82% increase from ¥2,153,183,204.74 in the previous year[20]. - The net assets attributable to shareholders of the listed company increased to ¥2,945,578,499.67, a significant rise of 143.14% from ¥1,211,492,918.48 at the end of the previous year[20]. - Total liabilities amounted to ¥1,007,370,589.93, up from ¥937,856,701.97, which is an increase of about 7.4%[158]. - Total equity attributable to shareholders rose to ¥2,945,578,499.67 from ¥1,211,492,918.48, showing a substantial increase of approximately 143.5%[158]. Research and Development - R&D investment totaled 10,872.64 million yuan, up 35.88% year-on-year, accounting for 7.05% of sales revenue[44]. - The company is focused on the research and development of drugs and medical devices, with a strong market presence in various therapeutic areas[27]. - The company aims to enhance its R&D capabilities by increasing the proportion of innovative drug development and improving the integration of raw material and formulation processes[28]. - The company has 23 generic drug projects and 5 innovative drug projects under research, indicating a strong R&D pipeline[39]. - The company is collaborating with prestigious universities such as Peking University and Tsinghua University to enhance its R&D capabilities, focusing on nucleic acid and protein degradation projects[49]. Sales and Marketing - The sales model includes both distribution and direct sales, with significant exports to regions such as Africa and Southeast Asia[33]. - The company has a diverse product portfolio in various therapeutic areas, including cardiovascular, chronic kidney disease, and diabetes, which has established a competitive advantage in niche markets[62]. - The company has maintained a good sales growth despite challenges from centralized procurement, focusing on expanding partnerships with major pharmacy chains[49]. - The company is enhancing its marketing resources by recruiting external talent and promoting internal candidates to strengthen its sales team[49]. Environmental Management - The company is committed to green development and has implemented energy-saving modifications to its equipment, achieving significant reductions in energy consumption[52]. - The company is actively managing safety and environmental standards, establishing a wastewater treatment research laboratory to improve its environmental management[52]. - The company has established wastewater treatment facilities that meet environmental discharge standards, with specific pollutant levels reported well below regulatory limits[74]. - The company’s wastewater discharge data for the first half of 2022 shows COD at 48 mg/l, significantly below the standard of 500 mg/l, with a total discharge of 0.785 million tons[74]. - The company has passed environmental impact assessments for all construction projects, ensuring compliance before project operation[102]. Shareholder and Governance - The company adheres to strict commitments regarding shareholding and stock transfer restrictions, ensuring compliance with regulatory requirements[111]. - The company has committed to not transferring or entrusting the management of shares held indirectly for 36 months post-IPO[120]. - The company emphasizes adherence to the Shanghai Stock Exchange's rules on shareholding and reduction practices[114]. - The company has disclosed that there are no undisclosed related party transactions as of the date of the commitment letter[124]. - The company will not seek preferential treatment from its subsidiaries in business operations compared to independent third parties[124]. Financial Position and Future Outlook - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[196]. - The company has allocated resources for research and development of new products, aiming to enhance its competitive edge in the market[196]. - The company reported a significant increase in cash flow from financing activities, amounting to approximately ¥1.55 billion, compared to ¥19.99 million in the previous year, mainly due to public stock issuance[55]. - The company is prepared to apply for extensions for consistency evaluations for essential drugs if necessary, to mitigate risks of registration loss[63].